FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 71930

News■ Unclear/unknown

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 20:53 UTC
LAST UPDATE2026-10-08 21:01 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

NHS collaboration supports DCVax production but company is OTC and speculative.

NWBio gains NHS support for DCVax production
CATALYST TO WATCH

Clinical trial progress or approvals

MAIN RISK

OTC stock, high speculative risk

FULL DISPATCH

BETHESDA, Md., Oct. 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant ("NHSBT") announce that...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

2 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · CONFIRMING2026-10-08 21:01 UTCOPEN RECEIPT →
№ 02prnewswireprnewswire.com · PRIMARY2026-10-08 20:53 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.